Roche's Kadcyla Approved in EU for Advanced HER2-Positive Breast Cancer

Roche (OTC: RHHBY ) today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. Specifically, Kadcyla is indicated as a single agent for